• 1
    Scher HI, Shipley WU, Herr HW. Cancer of the bladder. In: DeVitaVTJr., HellmanS, RosenbergSA, editors. Cancer principles and practice of oncology, 5th edition. Philadelphia: Lippincott-Raven, 1997: 13001322.
  • 2
    Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer. 1989; 64: 24482458.
  • 3
    Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma of the bladder: a cooperative group study. J Clin Oncol. 1992; 10: 10661073.
  • 4
    Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990; 8: 10501055.
  • 5
    van der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol. 2000; 18: 30683077.
  • 6
    Gitlitz BJ, Baker C, Chapman Y, et al. A Phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003; 98: 18631869.
  • 7
    Roth B, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994; 12: 22642270.
  • 8
    McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15: 18531857.
  • 9
    Stadler WM, Kuzer T, Roth B, et al. A Phase II trial of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15: 33943398.
  • 10
    Vaughn DJ, Manola J, Dreicer R, et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction. A trial of the Eastern Cooperative Oncology Group. Cancer. 2002; 95: 10221027.
  • 11
    Moore M, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1999; 17: 28762881.
  • 12
    Nogue-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urothelial tract. An alternative therapy. Cancer. 2003; 97: 21802186.
  • 13
    Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001; 19: 30183024.
  • 14
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 17481756.
  • 15
    Kaplan EL, Meier P. Nonparametric estimates from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 16
    Hainsworth JD, Burris HA, Erland JB, et al. Phase I/II trial of paclitaxel by one-hour infusion, carboplatin, and gemcitabine in the treatment of advanced non-small cell lung cancer. Cancer. 1999; 85: 12691277.
  • 17
    Greco FA, Burris HA, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002; 20: 16511656.
  • 18
    Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001; 19: 25272533.